mGluR5 NAM for Stroke Recovery (dipraglurant via Addex)
Recovery of brain function after stroke/brain injury
Phase 2 ReadyActive
Key Facts
Indication
Recovery of brain function after stroke/brain injury
Phase
Phase 2 Ready
Status
Active
Company
About Sinntaxis
Sinntaxis is a private, preclinical-stage biotech company targeting the significant unmet need for post-stroke recovery therapies. Its core technology involves inhibiting mGluR5 to beneficially remodel brain connectivity and enhance functional recovery, even when treatment begins days after the stroke event. The company has filed foundational IP, secured non-dilutive grant funding, and entered a strategic collaboration with Addex Therapeutics to advance dipraglurant, a phase II-ready candidate, for brain injury recovery.
View full company profile